Market Overview

UPDATE: Stifel Nicolaus Raises PT to $38 on Align Technology on Trial Outlook

Share:
Related ALGN
Benzinga's Top Upgrades, Downgrades For January 19, 2018
Jim Cramer Gives His Opinion On Align Technology And Monsanto

Stifel Nicolaus reiterated its Buy rating on Align Technology (NASDAQ: ALGN) and raised the price target from $32.00 to $38.00.

Stifel Nicolaus said, "Align's patent infringement trial against ClearCorrect is scheduled to begin today. … With the limited information contained in the public filings, Mr. Lavelle acknowledged it would be difficult to handicap the potential outcome of the trial. That said, he seems to think Align has a strong position, given the broad claims covered by the seven patents being asserted against ClearCorrect as well as Align's prior success with some of these same patents in prior litigation with OrthoClear. Additionally, two of the seven patents were recently re-validated by the United States Patent and Trademark Office (USPTO), which likely mitigates ClearCorrect's ability to claim the patents are invalid."

Align Technology closed at $31.90 on Friday.

Latest Ratings for ALGN

DateFirmActionFromTo
Jan 2018Stephens & Co.DowngradesOverweightEqual-Weight
Dec 2017Deutsche BankInitiates Coverage OnHold
Oct 2017Credit SuisseMaintainsOutperform

View More Analyst Ratings for ALGN
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Analyst Ratings

 

Related Articles (ALGN)

View Comments and Join the Discussion!